We support bridging studies and combined Phase I–IIa designs to efficiently transition compounds from early safety evaluation into proof-of-concept. These studies are tailored to link populations, formulations, or dosing regimens while maintaining regulatory alignment. Our flexible operational setup allows seamless progression from healthy volunteers to selected patient cohorts, reducing development timelines and maximizing data value.
Ethics Committee approval for all studies
Medical supervision by experienced clinical staff
Clear participant information and informed consent
Conducted in compliance with ICH-GCP and EU regulations
